[Monoclonal antibodies in infectious diseases: new partners in the therapeutic arsenal].
Guillaume DesoubeauxMireia PelegrinPublished in: Medecine sciences : M/S (2020)
Development of therapeutic antibodies for treating infectious diseases is more recent than for cancer and inflammatory diseases. To date, seven antibodies have been approved worldwide and only five in France. Medical indications are so far limited to the prophylaxis of bronchiolitis caused by respiratory syncytial virus (RSV), treatment of multidrug-resistant HIV disease, exposure to rabies and anthrax pulmonary disease, prevention of diarrhea recurrence due to Clostridium difficile, and atypical hemolytic uremic syndrome caused by Escherichia coli. In a near future, new technologies would allow accelerating the development of anti-infectious monoclonal antibodies to improve the anti-bacterial and anti-viral therapeutic arsenal.
Keyphrases
- infectious diseases
- respiratory syncytial virus
- clostridium difficile
- multidrug resistant
- escherichia coli
- hiv testing
- healthcare
- hiv infected
- antiretroviral therapy
- human immunodeficiency virus
- papillary thyroid
- pulmonary hypertension
- hiv positive
- sars cov
- hepatitis c virus
- drug resistant
- cystic fibrosis
- klebsiella pneumoniae
- men who have sex with men
- current status
- hiv aids
- case report
- acinetobacter baumannii
- squamous cell carcinoma
- pseudomonas aeruginosa
- squamous cell
- biofilm formation
- irritable bowel syndrome
- young adults
- respiratory tract
- south africa